The sales of Cardiac Glycosides in Finland are forecasted to remain flat from 2024 to 2028 at 1.1 million euros annually, showing no year-on-year variation in this period. The actual sales data for 2023 stood at the same value of 1.1 million euros, indicating no growth or decline leading into the forecast period. Given the stability of the value, the CAGR over the next 5 years is 0%, reflecting a stagnant market.
Future trends to watch for include potential changes in healthcare policies and advancements in alternative treatments which may impact the demand for Cardiac Glycosides. Additionally, shifts in demographic health dynamics and the entrance of new pharmaceutical players might also affect the market landscape.
